Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2010

01-11-2010 | Translational Research and Biomarkers

Abnormal Expression of PFDN4 in Colorectal Cancer: A Novel Marker for Prognosis

Authors: Norikatsu Miyoshi, MD, Hideshi Ishii, MD, Koshi Mimori, MD, Naohiro Nishida, MD, Masayoshi Tokuoka, MD, Hirofumi Akita, MD, Mitsugu Sekimoto, MD, Yuichiro Doki, MD, PhD, Masaki Mori, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 11/2010

Login to get access

Abstract

Background

Prefoldin 4 (PFDN4) is a transcriptional factor that regulates the cell cycle. PFDN4 is upregulated in breast tumor and breast cancer cell lines, but its significance in colorectal cancer (CRC) is not fully understood.

Methods

The present study assessed 129 patients who underwent surgery for CRC and assessed three cell lines derived from human CRC. The correlation of gene expression with clinical parameters in patients was assessed by knockdown experiments with these cell lines.

Results

Patients with high PFDN4 expression had a statistically relatively better prognosis, and those with low PFDN4 expression showed poorer overall survival than those with high expression. The assessment of PFDN4 knockdown in the three cell lines demonstrated that the siRNA inhibition resulted in a statistically significant increase in cell growth and invasiveness.

Conclusions

The data strongly suggest that PFDN4 expression is a prognostic factor in CRC.
Appendix
Available only for authorised users
Literature
1.
2.
Jones OM, John SK, Horseman N, et al. Cause and place of death in patients dying with colorectal cancer. Colorectal Dis. 2007;9:253–7.CrossRefPubMed
3.
Kohno SI, Luo C, Nawa A, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 2007;14:918–26.CrossRefPubMed
4.
Yamasaki M, Takemasa I, Komori T, et al. The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol. 2007;30:129–38.PubMed
5.
Aliaga JC, Deschenes C, Beaulieu JF, et al. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells. Am J Physiol. 1999;277(3 Pt 1):G631–41.PubMed
6.
Yamatodani T, Ekblad L, Kjellen E, et al. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol. 2009;135:395–402.CrossRefPubMed
7.
Collins C, Volik S, Kowbel D, et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res. 2001;11:1034–42.CrossRefPubMed
8.
Vainberg IE, Lewis SA, Rommelaere H, et al. Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell. 1998;93:863–73.CrossRefPubMed
9.
Japanese Society for Cancer of the Colon and Rectum. Guidelines for therapy of colorectal cancer (in Japanese). Tokyo: Kanehara Shuppan; 2005.
10.
Sobin LH, Witedkind CH. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss; 1997. p. 66–9.
11.
Christensen TG, Burke B, Dexter DL, Zamcheck N. Ultrastructural evidence of dimethylformamide-induced differentiation of cultured human colon carcinoma cells. Increased expression of desmosomes. Cancer. 1985;56:1559–65.CrossRefPubMed
12.
Ishizu K, Sunose N, Yamazaki K, et al. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull. 2007;30:1779–83.CrossRefPubMed
13.
Aznavoorian S, Liotta LA, Kupchik HZ. Characteristics of invasive and noninvasive human colorectal adenocarcinoma cells. J Natl Cancer Inst. 1990;82:1485–92.CrossRefPubMed
14.
Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76:531–6.PubMed
15.
Mori M, Staniunas RJ, Barnard GF, et al. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 1993;105:820–6.PubMed
16.
Tsujino T, Seshimo I, Yamamoto H, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007;13:2082–90.CrossRefPubMed
17.
Lagers AM, Sier CF, Hawinkels LJ, et al. MMP-2 geno-phenotype is prognostic factor for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer. 2008;98:1820–3.CrossRef
18.
Iijima M, Kano Y, Nohno T, Namba M. Cloning of cDNA with possible transcription factor activity at the G1-S phase transition in human fibroblast cell lines. Acta Med Okayama. 1996;50:73–7.PubMed
19.
Hansen WJ, Cowan NJ, Welch WJ. Prefoldin-nascent chain complexes in the folding of cytoskeletal proteins. J Cell Biol. 1999;145:265–77.CrossRefPubMed
20.
Hodgson G, Hager JH, Volik S, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet. 2001;29:459–64.CrossRefPubMed
21.
Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–8.CrossRefPubMed
22.
Wolpin BM. Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296–310.CrossRefPubMed
23.
Kornmann M, Formentini A, Ette C, et al. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 2008;34:1316–21.PubMed
24.
Bathe OF, Dowden S, Sutherland F, et al. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 2004;4:32.CrossRefPubMed
25.
Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–9.CrossRefPubMed
26.
Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–8.CrossRefPubMed
27.
Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–9.CrossRef
28.
Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.CrossRefPubMed
29.
Koshariya M, Jagad RB, Kawamoto J, et al. An update and our experience with metastatic liver disease. Hepatogastroenterology. 2007;54:2232–9.PubMed
Metadata
Title
Abnormal Expression of PFDN4 in Colorectal Cancer: A Novel Marker for Prognosis
Authors
Norikatsu Miyoshi, MD
Hideshi Ishii, MD
Koshi Mimori, MD
Naohiro Nishida, MD
Masayoshi Tokuoka, MD
Hirofumi Akita, MD
Mitsugu Sekimoto, MD
Yuichiro Doki, MD, PhD
Masaki Mori, MD, PhD, FACS
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1138-5

Other articles of this Issue 11/2010

Annals of Surgical Oncology 11/2010 Go to the issue

Endocrine Tumors

25-Hydroxyvitamin D Status Does Not Affect Intraoperative Parathyroid Hormone Dynamics in Patients with Primary Hyperparathyroidism

Colorectal Cancer

Robotic Right Colon Resection: Evaluation of First 50 Consecutive Cases for Malignant Disease

Head and Neck Oncology

Tongue and Buccal Mucosa Carcinoma: Is There a Difference in Outcome?

Translational Research and Biomarkers

Clinical Significance of Human Kallikrein7 Gene Expression in Colorectal Cancer

Breast Oncology

The Effect of Simultaneous Peripheral Excision in Breast Conservation upon Margin Status

Breast Oncology

Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy